ASCO GUIDELINES Bundle

Smal Renal Masses

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/786165

Contents of this Issue

Navigation

Page 1 of 3

Key Points ➤ ASCO defines small renal masses (SRMs) as incidentally image-detected, contrast-enhancing renal tumors ≤4 cm in diameter that are usually consistent with stage T1a renal cell carcinoma. ➤ On rare occasions, SRMs may be unusual malignant tumor types such as lymphoma, sarcoma, or a metastasis to the kidney. ➤ More than one imaging modality may be required to confirm that the lesion is solid and/or enhancing. ➤ With more widespread use of axial imaging, usually ordered for nonspecific gastrointestinal or musculoskeletal symptoms, there has been a continued increase in the rate of incidentally detected SRMs. ➤ As many as 25% of SRMs are benign renal cortical tumors (eg, oncocytoma, metanephric adenoma, and angiomyolipoma), and another 25% are indolent in nature with limited metastatic potential (eg, chromophobe, type 1 papillary renal cancer). • Although certain renal tumor histologies have distinct imaging characteristics, current radiologic imaging cannot reliably discriminate benign from indolent or potentially malignant tumors. In addition to the diagnostic dilemma, the natural history of these lesions is variable, and many tumors demonstrate an indolent course. Diagnosis ➤ On the basis of tumor-specific findings and competing risks of mortality, all patients with an SRM should be considered for renal tumor biopsy when the results may alter management (Strong Recommendation: EB-I). ➤ Active surveillance should be an initial management option for patients who have significant comorbidities and limited life expectancy (Moderate Recommendation: EB-I). Qualifying statement: ▶ Absolute indication: high risk for anesthesia and intervention or life expectancy <5 years ▶ Relative indication: significant risk of end-stage renal disease if treated, SRM (<1 cm), or life expectancy <10 years ➤ Partial nephrectomy (PN) for SRMs is the standard treatment that should be offered to all patients in whom an intervention is indicated and who possess a tumor amenable to this approach (Strong Recommendation: EB-I). Treatment

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Smal Renal Masses